A wound dressing that fights infection only when infection arrives

Brown University

Every year, more than a million people die from infections that no longer respond to antibiotics. The toll is projected to approach 10 million annual deaths by 2050 if antibiotic overuse continues unchecked. A significant chunk of that overuse happens at the skin's surface, where standard wound dressings soak tissue in antimicrobial agents whether bacteria are present or not.

A team of biomedical engineers at Brown University asked a pointed question: what if the dressing itself could tell the difference?

A crosslinker that listens for danger

The material they built is a hydrogel — a water-rich, Jell-O-like matrix of long polymer chains held together by smaller molecules called crosslinkers. In a conventional hydrogel, those crosslinkers are chemically inert. In this version, they are designed to break apart when they encounter beta-lactamases, a class of enzymes produced by a wide variety of pathogenic bacteria. When the crosslinkers degrade, the hydrogel's structure collapses, and antibiotic cargo trapped inside spills out directly onto the wound.

When no harmful bacteria are present, the gel holds firm. The drug stays locked inside. Anita Shukla, the Brown engineering professor who led the work, emphasized this point: the formulation does not leak. The antibiotic remains physically trapped in the polymer matrix until beta-lactamase production reaches a level sufficient to trigger degradation.

Sorting friend from foe in a petri dish

The research team, publishing their results in Science Advances, first tested selectivity in vitro. They exposed the hydrogel to bacteria that produce beta-lactamases and to harmless bacteria that do not. The gel degraded only in the presence of the enzyme-producing pathogens. Critically, the harmless bacteria — representatives of the kind of microbes that make up healthy skin flora — did not trigger any drug release. Long-term exposure of these non-pathogenic bacteria to the intact hydrogel produced no antibiotic resistance development, a result that matters as much as the drug delivery itself.

That selectivity is the core design principle. Conventional antimicrobial dressings, including silver-based formulations widely used in clinical settings, release their active agents continuously. They kill bacteria indiscriminately — pathogens and beneficial microbes alike — and the constant low-level exposure creates exactly the selection pressure that breeds resistant strains.

One application, full clearance

The team moved to mouse models with abrasion wounds infected by pathogenic bacteria. A single application of the smart hydrogel fully eradicated the bacterial infection. Compared head-to-head with a commercially available antimicrobial dressing currently used in clinical wound care, the new material performed better on two measures: bacterial clearance and wound healing speed.

That dual advantage matters. Clearing an infection quickly is only half the job; the wound still needs to close. Standard antimicrobial dressings can impede healing by damaging healthy tissue and disrupting the skin's microbial ecosystem. A dressing that intervenes only when needed avoids that collateral damage.

The resistance math

The scale of the antimicrobial resistance crisis gives this kind of targeted approach its urgency. According to a 2022 analysis published in The Lancet, bacterial antimicrobial resistance was directly responsible for 1.27 million deaths globally in 2019 and contributed to nearly 5 million more. Wound infections are a significant contributor to that burden, particularly in surgical settings and chronic wound care for diabetic and elderly patients.

Every unnecessary antibiotic exposure — every bandage leaking silver ions into intact skin — adds to the evolutionary pressure that selects for resistant organisms. The logic of the Brown team's approach is straightforward: eliminate the unnecessary exposures. Deliver the drug precisely when and where the pathogen demands it, and only then.

What the hydrogel cannot do yet

There are important caveats. The mouse experiments used a single bacterial species to create the wound infections, and real-world wounds often harbor polymicrobial communities. The beta-lactamase trigger is broad — many different pathogenic species produce these enzymes — but it is not universal. Some dangerous wound pathogens may not produce beta-lactamases in sufficient quantities to trigger the hydrogel, which could leave infections untreated.

The study also tested only one antibiotic cargo. Whether the hydrogel's release kinetics and efficacy hold across different drug classes remains to be demonstrated. And while the mouse model results are encouraging, translating wound-healing outcomes from rodents to human skin — with its different thickness, vasculature, and immune environment — is notoriously difficult. These are preclinical results, and a clinical product could be years away.

The research team has patented the material and is working toward further development for potential commercialization, though no timeline for human trials has been announced.

A smarter bandage, not a miracle

The appeal of this approach lies in its modesty. It does not attempt to reinvent antibiotics or discover new drug targets. It takes existing drugs and delivers them more intelligently. The hydrogel is a logistics solution to a logistics problem: antibiotics work, but we waste them, and that waste is killing people.

Whether this particular material reaches patients will depend on manufacturing scalability, regulatory clearance, shelf-life stability, and a dozen other factors that laboratory studies cannot address. But the principle it demonstrates — that wound dressings can be engineered to sense their environment and respond accordingly — opens a design space that extends well beyond this single prototype.

The work was supported by the Dr. Ralph and Marian Falk Medical Research Trust.